



09-15-05

PCT  
JC06 Rec'd PCT/PTO 13 SEP 2005

Docket No.: 03818/0202984-US0  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Nedjeljko Kujundzic et al.

Application No.: 10/538,376

Filed: June 13, 2005

Art Unit: To Be Assigned

For: NOVEL SEMISYNTHETIC MACROLIDE  
ANTIBIOTICS OF THE AZALIDE SERIES

Examiner: To Be Assigned

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed within three months of the date of entry of the national stage of an international application as set forth in 37 CFR 1.491 (37 CFR 1.97(b)(2)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

Three of the references for this Information Disclosure Statement were cited in an International Search Report for International application no. PCT/HR03/00062. A copy of the International Search Report is enclosed.


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: September 13, 2005

Respectfully submitted,

By  REGISTRATION No. 59,781 for  
Lydia Gayle Olson  
Registration No.: 48,487  
DARBY & DARBY P.C.  
P.O. Box 5257  
New York, New York 10150-5257  
(212) 527-7700  
(212) 527-7701 (Fax)  
Attorneys/Agents For Applicant



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/538,376
Filing Date	June 13, 2005
First Named Inventor	Nedjeljko Kujundzic
Art Unit	To Be Assigned
Examiner Name	To Be Assigned
Attorney Docket Number	03818/0202984-US0

Sheet 1 of 1

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA	US 4,492,688	01-08-1985	Bright	
	AB	US 4,474,768	10-02-1984	Bright	
	AC	US 4,328,334	05-04-1982	Kobrehel, et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	BA	WO 97/35590	10-02-1997	Platt		
	BB	EP 0 316 128	05-17-1989	Pfizer Inc. (Bright)		
	BC	EP 0 132 944	12-30-1986	Pfizer Inc. (Bright)		
	BD	BE 892,397	03-08-1982	Marchand		
	BE	FR 2 473 525	07-17-1981	Roussel-Uclaf		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	Puri, S.K., and Singh, Naresh. 2000. Azithromycin: Antimalarial Profile against Blood- and Sporozoite-Induced Infections in Mice and Monkeys. <i>Experimental Parasitology</i> 94:8-14.	
	CB	Sadiq, S.T., et al. 1995. Effects of azithromycin on malariometric indices in The Gambia. <i>The Lancet</i> 346:881-882.	
	CC	Kobrehel, Gabrijela, et al. 1993. 9a,11-Cyclic Carbamates of 15-Membered Azalides. <i>The Journal of Antibiotics</i> 46(8):1239-1245.	
	CD	Luger, Peter, and Maier, Roland. 1979. Molecular structure of 9-deoxy-11-deoxy-9-11-(imino(2-(2-methoxyethoxy)ethylidene)oxy)-(9S)-erythromycin, a new erythromycin derivative. <i>Journal of Crystal and Molecular Structure</i> 9(6):329-338.	
	CE	Egan, Richard S., et al. 1974. Configuration of 9-Imino Derivatives of Erythromycin. <i>J. Org. Chem.</i> 39(17):2492-2494.	
	CF	Kurath, P., et al. 1971. Acid Degradation of Erythromycin A and Erythromycin B. <i>Experientia</i> 27(4):362.	
	CG	Djokic, Slobodan, and Tamburasev, Zrinka. 1967. Erythromycin Study: 9-amino-3-O-cladinosyl-5-O-desoaminyl-6,11,12-trihydroxy-2,4,6,8,10,12-hexamethylpentadecame-13-olide. <i>Tetrahedron Letters</i> 17:1645-1647.	
	CH	McGuire, J.M. et al. 1952. "Ilotycin," A New Antibiotic. <i>Antibiotics and Chemotherapy</i> 11(6): 281-283.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Examiner Signature	Date Considered
--------------------	-----------------

Attorney Docket No.: 03818/0202984-US0


# Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. \_\_\_\_\_ in an envelope addressed to:

EV691013745-US

**MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450**

on September 13, 2005  
Date

  
Signature

Lillian Garcia  
Typed or printed name of person signing Certificate

Registration Number, if applicable	Telephone Number

**Note:** Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Information Disclosure Statement (2 pages)  
International Search Report (PCT/HR03/00062, 3 pages)  
PTO/SB/08a/b (1 page) and 13 References  
Return Receipt Postcard